Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion

This study is a single-center, crossover clinical trial in which each participant serves as their own control. The aim is to evaluate the effects of the WM Formula dietary supplement on promoting endogenous GLP-1 secretion and suppressing appetite in adults with elevated body fat percentage. Eligible participants will be adults aged 18 years or older, screened based on body fat percentage. Inclusion criteria: -Body fat percentage ≥30% for females or ≥25% for males. Exclusion criteria: * Prior use of GLP-1 receptor agonists approved in Taiwan (e.g., liraglutide, semaglutide, dulaglutide), * Use of blood glucose-regulating medications, * Presence of major organic diseases, Or a history of hypoglycemia. After enrollment, participants will be required to visit TCI Co., Ltd. for blood collection, height and body composition measurements, and completion of questionnaires. Each study visit will take approximately 5 hours, and participants will undergo two test sessions, separated by a 7-day washout period (i.e., after completing the first test, the second will occur at least 7 days later). On each test day, blood samples (\~14 mL per time point) will be collected via an indwelling venous catheter at the following time points: before ingestion of the test product or water, and at 15, 30, 45, 60, 90, 120, and 240 minutes post-ingestion. The blood samples will be analyzed for GLP-1, DPP-4, complete blood count (CBC), blood glucose, and insulin concentrations.